JP2016519116A - アフィニティー樹脂を使用するadcの合成方法 - Google Patents
アフィニティー樹脂を使用するadcの合成方法 Download PDFInfo
- Publication number
- JP2016519116A JP2016519116A JP2016509554A JP2016509554A JP2016519116A JP 2016519116 A JP2016519116 A JP 2016519116A JP 2016509554 A JP2016509554 A JP 2016509554A JP 2016509554 A JP2016509554 A JP 2016509554A JP 2016519116 A JP2016519116 A JP 2016519116A
- Authority
- JP
- Japan
- Prior art keywords
- biomolecule
- protein
- antibody
- drug
- capture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
(i)生体分子と捕捉樹脂とを、生体分子を固定化するために適切な条件下で接触させ、それによって、固定化生体分子を提供し、該生体分子が抗体、改変抗体又は抗体断片であり、該捕捉樹脂が、(1)アミノ酸系、プロテインA、プロテインG又はプロテインL模倣体を含む非ペプチド系、(2)ペプチド系のプロテインA、プロテインG又はプロテインL模倣体、(3)ヌクレオチド結合部位捕捉部分及び(4)糖タンパク質捕捉部分、からなる群から選択される生体分子捕捉部分を含む工程、
(ii)場合により、固定化生体分子と化学的改変剤又は活性化剤とを接触させて、化学的に改変された、又は活性化された固定化生体分子を提供する工程、
(iii)固定化生体分子又は化学的に改変された、若しくは活性化された固定化生体分子と、薬物成分とを接触させて、生体分子薬物複合体を形成する工程、
(iv)生体分子薬物複合体を捕捉樹脂から放出する工程、
を含む。
(i)生体分子と捕捉樹脂とを、生体分子を固定化するために適切な条件下で接触させ、それによって、固定化生体分子を提供し、該生体分子が抗体、改変抗体又は抗体断片であり、該捕捉樹脂が、(1)アミノ酸系、プロテインA、プロテインG又はプロテインL模倣体を含む非ペプチド系、(2)ペプチド系のプロテインA、プロテインG又はプロテインL模倣体、(3)ヌクレオチド結合部位捕捉部分及び(4)糖タンパク質捕捉部分、からなる群から選択される生体分子捕捉部分を含む工程、並びに
(ii)固定化生体分子と化学的改変剤又は活性化剤とを接触させて、化学的に改変された、又は活性化された固定化生体分子を提供する工程、
を含む。
1.媒体に添加された非天然アミノ酸
2.直交アミノアシル−tRNAシンセターゼ(aaRS)
3.直交tRNA
を発現系に包含することによって、非天然アミノ酸を異種タンパク質に組み込むプラットホームである。
a)支持体−生体分子化合物を放出剤に曝露する工程、及び/又は
b)pHを変更して、支持体−生体分子の結合を破壊する工程、
を伴う。
(i)(1)非ペプチド系プロテインA、プロテインG又はプロテインL模倣体、(2)ペプチド系プロテインA、プロテインG又はプロテインL模倣体、(3)ヌクレオチド結合部位捕捉部分及び(4)糖タンパク質捕捉部分、からなる群から選択される抗体、改変抗体又は抗体断片捕捉部分を含む捕捉樹脂、並びに
(ii)化学的改変剤又は活性化剤
を含む混合物が提供される。
1.高度な初期精製を可能にする、抗体に対する高い選択性
2.有用な動的結合能
3.抗体完全性の保持と適合性の溶出条件
4.複数の溶出/クリーニングサイクルの間の支持体の安定性
5.プロテインA、G又はL系支持体と比較して低コスト
であった。
固相抗体薬物複合体のスクリーニング
バッチモードの固相部分的TCEP還元
カラムにおける固相部分的TCEP還元
リジン側鎖のSMCC活性化を介した、バッチモードにおけるDM1との固相ハーセプチン複合体化
Claims (31)
- 生体分子薬物複合体を合成する方法であって、
(i)生体分子と捕捉樹脂とを、生体分子を固定化するために適切な条件下で接触させ、それによって、固定化生体分子を提供し、該生体分子が抗体、改変抗体又は抗体断片であり、該捕捉樹脂が、(1)アミノ酸系、プロテインA、プロテインG又はプロテインL模倣体を含む非ペプチド系、(2)ペプチド系のプロテインA、プロテインG又はプロテインL模倣体、(3)ヌクレオチド結合部位捕捉部分及び(4)糖タンパク質捕捉部分、からなる群から選択される生体分子捕捉部分を含む工程、
(ii)場合により、固定化生体分子と化学的改変剤又は活性化剤とを接触させて、化学的に改変された、又は活性化された固定化生体分子を提供する工程、
(iii)固定化生体分子又は化学的に改変された、若しくは活性化された固定化生体分子と、薬物成分とを接触させて、生体分子薬物複合体を形成する工程、
(iv)生体分子薬物複合体を捕捉樹脂から放出する工程
を含む方法。 - 工程(i)が、生体分子と捕捉樹脂とをインキュベートする工程を含む、請求項1に記載の方法。
- インキュベーションが、約10から約40℃、場合により約15から約37℃の温度において実施される、請求項2に記載の方法。
- インキュベーションが、約10分から約18時間の期間実施される、請求項2又は請求項3に記載の方法。
- インキュベーションが、バッファー溶液、場合によりリン酸緩衝生理食塩水(PBS)中で実施される、請求項2から4のいずれかに記載の方法。
- インキュベーションが、約5から約8のpHにおいて実施される、請求項2から5のいずれかに記載の方法。
- 工程(i)の後で、固定化生体分子が洗浄され、捕捉樹脂に固定化されなかったすべての生体分子が除去される、請求項1から6のいずれかに記載の方法。
- 工程(ii)が、生体分子を還元する工程を伴う、請求項1から7のいずれかに記載の方法。
- 生体分子が、生体分子と還元剤、例えば、トリス(2−カルボキシエチル)ホスフィン(TCEP)、ジチオスレイトール(DTT)、メルカプトエチルアミン(merceptoethylamine)又は他の適切な還元剤とを接触させる工程により還元される、請求項8に記載の方法。
- 工程(ii)が、生体分子と架橋剤部分とを反応させる工程を伴い、場合により、前記架橋剤部分がスクシンイミジル4−(N−マレイミドメチル)シクロヘキサン−1−カルボキシレート(SMCC)である、請求項1から7のいずれかに記載の方法。
- 工程(ii)が、バッファー溶液、例えばリン酸緩衝生理食塩水(PBS)中で実施される、請求項8から10のいずれかに記載の方法。
- 工程(ii)が、約7から約8のpHにおいて実施される、請求項8から11のいずれかに記載の方法。
- 工程(ii)が、キレート剤、例えばEDTAの存在下で実施される、請求項8から12のいずれかに記載の方法。
- 工程(ii)が、生体分子と還元剤とを、約6時間から約18時間の期間インキュベートする工程を伴う、請求項8から13のいずれかに記載の方法。
- 工程(ii)の後で、活性化された固定化生体分子が洗浄され、すべての改変剤/活性化剤が除去される、請求項1から14のいずれかに記載の方法。
- 工程(iii)が、化学的に改変された、又は活性化された固定化生体分子と薬物成分とを、バッファー溶液中で接触させる工程を伴う、請求項1から15のいずれかに記載の方法。
- 工程(iii)が、化学的に改変された、又は活性化された固定化生体分子と薬物成分とを、約7から約8、好ましくは約7.4のpHにおいて接触させる工程を伴う、請求項1から16のいずれかに記載の方法。
- 工程(iii)が、キレート剤、例えばEDTAの存在下で実施される、請求項1から17のいずれかに記載の方法。
- 工程(iii)が、化学的に改変された、又は活性化された固定化生体分子と薬物成分とを、約6時間から約18時間の期間インキュベートする工程を伴う、請求項1から18のいずれかに記載の方法。
- 工程(iii)の後で、固定化生体分子薬物複合体が洗浄され、すべての未反応の薬物成分が除去される、請求項1から19のいずれかに記載の方法。
- 工程(iv)が、pHを変更して、支持体−生体分子の結合を破壊する工程を伴う、請求項1から20のいずれかに記載の方法。
- pHが、約pH5未満、場合により約pH3に低下される、請求項21に記載の方法。
- 溶出された生体分子薬物複合体が、捕捉樹脂から複合体を放出する工程の後で中和され、場合により、前記複合体が、2%v/vの1M トリス(ヒドロキシメチル)アミノエタン(TRIS)中に捕捉される、請求項21又は22に記載の方法。
- (i)(1)非ペプチド系プロテインA、プロテインG又はプロテインL模倣体、(2)ペプチド系プロテインA、プロテインG又はプロテインL模倣体、(3)ヌクレオチド結合部位捕捉部分、並びに(4)糖タンパク質捕捉部分からなる群から選択される、抗体、改変抗体又は抗体断片捕捉部分を含む、捕捉樹脂、並びに
(ii)化学的改変剤又は活性化剤
を含む混合物。 - 捕捉樹脂が、固定化された抗体、改変抗体又は抗体断片をこれらの表面に含む、請求項24に記載の混合物。
- (1)非ペプチド系プロテインA、プロテインG又はプロテインL模倣体、(2)ペプチド系プロテインA、プロテインG又はプロテインL模倣体、(3)ヌクレオチド結合部位捕捉部分及び(4)糖タンパク質捕捉部分からなる群から選択される抗体、改変抗体又は抗体断片捕捉部分を含む捕捉樹脂の、生体分子薬物複合体の合成における使用。
- 捕捉樹脂が非タンパク質性捕捉樹脂である、請求項1から26のいずれかに記載の方法、混合物又は使用。
- 捕捉樹脂の生体分子捕捉部分が、約1000Da以下の分子量を有する、請求項1から27のいずれかに記載の方法、混合物又は使用。
- 捕捉樹脂のリガンドが、構造:
- 生体分子が抗体であり、場合により、前記抗体が、モノクローナル抗体である、及び/又は前記抗体がトラスツズマブである、請求項1から29のいずれかに記載の方法、混合物又は使用。
- 薬物が、チューブリン阻害剤又はDNA相互作用剤であり、場合により前記チューブリン阻害剤が、(a)オーリスタチン及び(b)メイタンシン誘導体からなる群から選択され、場合により、前記DNA相互作用剤が、(a)カリケアマイシン、(b)デュオカルマイシン及び(c)ピロロベンゾジアゼピン(PBD)からなる群から選択される、請求項1から30のいずれかに記載の方法、混合物又は使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1307574.2 | 2013-04-26 | ||
GB1307574.2A GB2513405A (en) | 2013-04-26 | 2013-04-26 | Method of synthesising ADCs using affinity resins |
PCT/GB2014/051304 WO2014174316A1 (en) | 2013-04-26 | 2014-04-25 | Method of synthesising adcs using affinity resins |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016519116A true JP2016519116A (ja) | 2016-06-30 |
JP6484607B2 JP6484607B2 (ja) | 2019-03-13 |
Family
ID=48626896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016509554A Expired - Fee Related JP6484607B2 (ja) | 2013-04-26 | 2014-04-25 | アフィニティー樹脂を使用するadcの合成方法 |
Country Status (13)
Country | Link |
---|---|
US (2) | US10201544B2 (ja) |
EP (1) | EP2988785B8 (ja) |
JP (1) | JP6484607B2 (ja) |
KR (1) | KR20160003080A (ja) |
CN (1) | CN105579066B (ja) |
AU (1) | AU2014259160B2 (ja) |
CA (1) | CA2910064C (ja) |
DK (1) | DK2988785T3 (ja) |
ES (1) | ES2658420T3 (ja) |
GB (1) | GB2513405A (ja) |
MX (1) | MX366908B (ja) |
NO (1) | NO2988785T3 (ja) |
WO (1) | WO2014174316A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201419184D0 (en) * | 2014-10-28 | 2014-12-10 | Adc Biotechnology Ltd | Method of synthesising biomolecule-effector/reporter-conjugates using affinity resins |
GB201419185D0 (en) * | 2014-10-28 | 2014-12-10 | Adc Biotechnology Ltd | Method of synthesising ADCs using affinity resin |
US10548986B2 (en) | 2016-03-02 | 2020-02-04 | Eisai R&D Management Co., Ltd. | Eribulin-based antibody-drug conjugates and methods of use |
RU2019134030A (ru) * | 2017-03-30 | 2021-04-30 | Цзянсу Хэнжуй Медисин Ко., Лтд. | Способ получения конъюгата антитело-лекарственное средство |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997010887A1 (en) * | 1995-09-20 | 1997-03-27 | Novo Nordisk A/S | Novel affinity ligands and their use |
WO1998008603A1 (en) * | 1996-08-30 | 1998-03-05 | Upfront Chromatography A/S | Isolation of immunoglobulins |
US20010045384A1 (en) * | 2000-04-28 | 2001-11-29 | Bozidar Stipanovic | Simulated activity of protein a displayed by ligands attached to a cellulose bead surface |
WO2004035199A1 (en) * | 2002-10-21 | 2004-04-29 | Cambridge University Technical Services Limited | Affinity adsorbents for immunoglobulins |
WO2009141384A2 (en) * | 2008-05-21 | 2009-11-26 | Novo Nordisk A/S | Process for the purification of factor vii polypeptides using affinity resins comprising specific ligands |
JP2011521909A (ja) * | 2008-05-16 | 2011-07-28 | フジフィルム・ダイオシンス・バイオテクノロジーズ ・ユーケイ・リミテッド | 誘導体化トリアジンをアフィニティーリガンドとして使用する抗体フラグメントの精製法 |
WO2011109308A1 (en) * | 2010-03-02 | 2011-09-09 | Seattle Genetics, Inc. | Methods for screening antibodies |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US6117996A (en) | 1995-09-20 | 2000-09-12 | Novo Nordisk A/S | Triazine based ligands and use thereof |
WO2003000176A2 (en) * | 2001-06-20 | 2003-01-03 | Molecular Staging, Inc. | Conjugates of reduced antibodies and biomolecules |
US20050276812A1 (en) * | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
WO2005039641A2 (en) * | 2003-10-15 | 2005-05-06 | The Regents Of The University Of California | Biomacromolecule polymer conjugates |
CN109045307A (zh) * | 2004-06-01 | 2018-12-21 | 健泰科生物技术公司 | 抗体-药物偶联物和方法 |
ITMI20071119A1 (it) | 2007-06-01 | 2008-12-02 | Tecnogen Spa | Nuovi ligandi sintetici per immunoglobuline e composizioni farmaceutiche che li comprendono |
US20090240033A1 (en) | 2008-03-11 | 2009-09-24 | Rongxiu Li | Affinity matrix library and its use |
WO2009117531A1 (en) * | 2008-03-18 | 2009-09-24 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
EP2277044B1 (en) * | 2008-05-13 | 2015-06-17 | Genentech, Inc. | Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry |
WO2012099949A2 (en) | 2011-01-18 | 2012-07-26 | University Of Notre Dame Du Lac | Antibody purification via affinity chromatography |
GB201106173D0 (en) * | 2011-04-12 | 2011-05-25 | Adc Biotechnology Ltd | System for purifyng, producing and storing biomolecules |
KR101972446B1 (ko) * | 2011-05-27 | 2019-04-25 | 글락소 그룹 리미티드 | Bcma(cd269/tnfrsf17)결합 단백질 |
-
2013
- 2013-04-26 GB GB1307574.2A patent/GB2513405A/en not_active Withdrawn
-
2014
- 2014-04-25 CA CA2910064A patent/CA2910064C/en not_active Expired - Fee Related
- 2014-04-25 EP EP14726715.7A patent/EP2988785B8/en active Active
- 2014-04-25 JP JP2016509554A patent/JP6484607B2/ja not_active Expired - Fee Related
- 2014-04-25 MX MX2015014935A patent/MX366908B/es active IP Right Grant
- 2014-04-25 WO PCT/GB2014/051304 patent/WO2014174316A1/en active Application Filing
- 2014-04-25 ES ES14726715.7T patent/ES2658420T3/es active Active
- 2014-04-25 US US14/786,387 patent/US10201544B2/en not_active Expired - Fee Related
- 2014-04-25 AU AU2014259160A patent/AU2014259160B2/en not_active Ceased
- 2014-04-25 NO NO14726715A patent/NO2988785T3/no unknown
- 2014-04-25 CN CN201480035757.2A patent/CN105579066B/zh not_active Expired - Fee Related
- 2014-04-25 KR KR1020157033519A patent/KR20160003080A/ko not_active Application Discontinuation
- 2014-04-25 DK DK14726715.7T patent/DK2988785T3/en active
-
2019
- 2019-01-31 US US16/263,757 patent/US20190216819A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997010887A1 (en) * | 1995-09-20 | 1997-03-27 | Novo Nordisk A/S | Novel affinity ligands and their use |
WO1998008603A1 (en) * | 1996-08-30 | 1998-03-05 | Upfront Chromatography A/S | Isolation of immunoglobulins |
US20010045384A1 (en) * | 2000-04-28 | 2001-11-29 | Bozidar Stipanovic | Simulated activity of protein a displayed by ligands attached to a cellulose bead surface |
WO2004035199A1 (en) * | 2002-10-21 | 2004-04-29 | Cambridge University Technical Services Limited | Affinity adsorbents for immunoglobulins |
JP2011521909A (ja) * | 2008-05-16 | 2011-07-28 | フジフィルム・ダイオシンス・バイオテクノロジーズ ・ユーケイ・リミテッド | 誘導体化トリアジンをアフィニティーリガンドとして使用する抗体フラグメントの精製法 |
WO2009141384A2 (en) * | 2008-05-21 | 2009-11-26 | Novo Nordisk A/S | Process for the purification of factor vii polypeptides using affinity resins comprising specific ligands |
WO2011109308A1 (en) * | 2010-03-02 | 2011-09-09 | Seattle Genetics, Inc. | Methods for screening antibodies |
Non-Patent Citations (2)
Title |
---|
PIGEON,C.J. ET AL.: "Application of Fabsorbent F1P HF, a synthetic ligand absorbent for capture and purification of a sin", BIOPROCESS INTERNATIONAL, vol. 7, no. 7, JPN6018003634, 1 July 2009 (2009-07-01), pages 90 - 1 * |
QIAN,J. ET AL.: "A synthetic protein G adsorbent based on the multi-component Ugi reaction for the purification of ma", J. CHROMATOGR. B ANALYT. TECHNOL. BIOMED. LIFE SCI., vol. Vol.898, JPN6018003633, 1 June 2012 (2012-06-01), pages 15 - 23 * |
Also Published As
Publication number | Publication date |
---|---|
CA2910064A1 (en) | 2014-10-30 |
KR20160003080A (ko) | 2016-01-08 |
MX366908B (es) | 2019-07-30 |
CN105579066B (zh) | 2019-03-12 |
EP2988785B1 (en) | 2017-11-01 |
CA2910064C (en) | 2019-07-23 |
US20160067352A1 (en) | 2016-03-10 |
EP2988785A1 (en) | 2016-03-02 |
GB2513405A (en) | 2014-10-29 |
CN105579066A (zh) | 2016-05-11 |
ES2658420T3 (es) | 2018-03-09 |
US10201544B2 (en) | 2019-02-12 |
MX2015014935A (es) | 2016-06-02 |
US20190216819A1 (en) | 2019-07-18 |
NO2988785T3 (ja) | 2018-03-31 |
AU2014259160B2 (en) | 2019-03-21 |
JP6484607B2 (ja) | 2019-03-13 |
WO2014174316A1 (en) | 2014-10-30 |
AU2014259160A1 (en) | 2015-11-19 |
DK2988785T3 (en) | 2018-02-05 |
EP2988785B8 (en) | 2018-04-04 |
GB201307574D0 (en) | 2013-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6955042B2 (ja) | 酵素的方法による均一抗体薬物コンジュゲート | |
US20210322561A1 (en) | Binding protein drug conjugates comprising anthracycline derivatives | |
Zhou et al. | Site-specific antibody–drug conjugation through glycoengineering | |
US20210401924A1 (en) | Stable antibody-drug conjugate, preparation method therefor, and use thereof | |
Sadowsky et al. | Development of efficient chemistry to generate site-specific disulfide-linked protein–and peptide–payload conjugates: application to THIOMAB antibody–drug conjugates | |
US20190216819A1 (en) | Method of synthesising adcs using affinity resins | |
Hui et al. | LASIC: Light activated site-specific conjugation of native IgGs | |
CN104853781B (zh) | 从含二硫化物的蛋白质制备缀合物的方法 | |
Li et al. | Stable and potent selenomab-drug conjugates | |
US20170326251A1 (en) | Method of synthesizing antibody drug conjugates using affinity resins | |
RU2582244C2 (ru) | Функционализированные полипептиды | |
US20230226208A1 (en) | Methods for the preparation of bioconjugates | |
EP3166644B1 (en) | Method of synthesising adcs using photocleavable linkers on solid support | |
Baeuerle et al. | Human therapies as a successful liaison between chemistry and biology | |
US20230338562A1 (en) | Methods for the preparation of linker payload constructs | |
Dovgan | Antibody conjugates: integrated approach towards selective, stable and controllable bioconjugation | |
Pabst et al. | Stable and Homogeneous Drug Conjugation by Sequential Bis-Alkylation at Disulphide Bonds Using Bis-Sulphone Reagents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170424 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180206 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180502 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180706 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180712 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190118 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190129 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190218 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6484607 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |